Cargando…
Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma
The treatment landscape of metastatic renal cell carcinoma (mRCC) has changed in the last decade with improvements in overall survival. Overall survival ranges from 57 months in good-to-intermediate prognosis patients to 19 months in poor prognosis patients. The most frequent sites of metastasis are...
Autores principales: | Vilaça, Marta, Braga, Fátima, Mesquita, Alexandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047437/ https://www.ncbi.nlm.nih.gov/pubmed/35494987 http://dx.doi.org/10.7759/cureus.23598 |
Ejemplares similares
-
Cutaneous and Cerebral Metastases From Primary Peritoneal Clear Cell Carcinoma
por: Alves, Fátima R, et al.
Publicado: (2022) -
The role of immunotherapy in non-clear cell renal cell carcinoma
por: Climent, Carla, et al.
Publicado: (2023) -
Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
por: An, Josiah, et al.
Publicado: (2022) -
Radiomics Analysis of Contrast-Enhanced CT Predicts Survival in Clear Cell Renal Cell Carcinoma
por: Yan, Lei, et al.
Publicado: (2021) -
Cellular milieu in clear cell renal cell carcinoma
por: Raghubar, Arti M., et al.
Publicado: (2022)